GENE ONLINE|News &
Opinion
Blog

2022-01-03| Asia-PacificIPO

RNAi Player Sirnaomics Squeezes in $50 Million IPO in Hong Kong

by Joy Lin
Share To

Sirnaomics, a RNA-focused company based in China and the US, raised a little over $50 million in its debut on the Stock Exchange of Hong Kong. The company offered a total of 7.54 million shares at HK$65.90. 

Kunming Jiashiqing and Innoforce Pharmaceuticals have been mentioned as cornerstone investors. 

Despite pricing its shares at the bottom of its predicted range of HK$65.90 to HK$72.70, Sirnaomics’ stock surged 18% on its first day, closing at HK$77.90, putting its market cap at $900 million.  

The public float comes five months after Sirnaomics closed a $105 million Series E round led by Rotating Boulder Fund. And just last year, the company raised the same amount in a Series D round co-led by Rotating Boulder Fund, Walvax Biotechnology and Sunshine Riverhead Capital. 

16 Clinical and Preclinical Assets

 

According to Sirnaomics, the majority of the proceeds would go into development and commercialization of its small interfering RNA (siRNA) lead pipeline candidate, STP705. Some of the funds will be set aside for other lead candidate STP707 and the GaINAc (N-Acetylgalactosamine) program, which designs liver-targeting siRNAs. The remainder of the proceeds will be used to develop preclinical candidates and support corporate expenses. 

RNA interference, also called RNA silencing, is a cellular gene inhibition mechanism likely evolved to combat foreign agents such as viruses. It typically involves RNA molecules that bind to a target mRNA, which inactivates the mRNA. Thus, the targeted proteins will not be translated and their expression drops. 

Sirnaomics’ STP705 is currently in a Phase 2 study in squamous cell skin cancer. The molecule targets TGF-β1 and COX-2 gene expression. The other lead candidate STP707, which targets the same genes, recently received the FDA go-ahead to begin a Phase 1 trial in solid advanced tumors. 

Besides the two candidates, Sirnaomics is also developing 14 other drugs that cover a variety of cancers, infectious diseases and fibrosis. 

RNA Silencing, a Rarity in China

 

RNAi is steadily gaining traction in China, with notable deals surfacing in recent months. 

Three weeks ago, Qilu Pharmaceutical struck a licensing agreement worth over $300 million with Arbutus for China rights to Arbutus’ AB-729, a treatment for hepatitis B virus (HBV) infection. 

On the other hand, Hansoh Pharma is turning out to be a major RNAi player in the Chinese market. Since October, the Shanghai-based company has struck three separate licensing deals with Keros, Silence and OliX for their RNAi therapeutics. The combined value of these deals is estimated to be nearly $2 billion.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Discover Investment Opportunities & Innovation at International Healthcare Week in Hong Kong from May
2025-05-12
ASGH and Hong Kong International Medical Fair 2025 Set to Transform Healthcare Landscape
2025-05-08
Trump’s Plan to Impose Major Drug Tariffs Sparks Fears Over Global Access and Pharma Supply Chains
2025-04-10
LATEST
Arkansas Bans Pharmacy Benefit Managers from Owning Pharmacies
2025-07-14
Air Pollution, Inequality, and Weak Democracies Linked to Faster Aging in Global Study
2025-07-14
Analysis Reveals Publication Bias in Scientific Research Dates Back to Modern Science’s Origins
2025-07-14
Oncology Pharmacists Tackle Biosimilar Integration and 505(b)(2) Drug Adoption at ATOPP 2025 Conference
2025-07-14
Pneumococcal Vaccination Linked to Lower Risk of Severe COVID-19 Outcomes in Patients with Inflammatory Rheumatic Diseases
2025-07-14
Telepharmacy and Mobile Units Address Medication Access in Pharmacy Deserts
2025-07-14
Board-Certified Psychiatric Pharmacists Address Behavioral Health Workforce Shortages with Expertise in Psychopharmacology
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top